13F Portfolios

Davern Capital Partners, LP: ROYALTY PHARMA PLC (RPRX): Quarterly 13F Position History

As of Q2 2026, Davern Capital Partners, LP reported 1,155,809 shares of ROYALTY PHARMA PLC (RPRX), worth $64.8M and representing 11.0% of its 13F equity book. Quarter-over-quarter share count change: + 635,800 (+122.3%) . The position first appeared in Q4 2025 and has been disclosed across 3 13F-HR filings in Pactolio's tracked window.

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q2 2026 1,155,809 +635,800 +122.3% $64.8M 11.0% $56.1
Q1 2026 520,009 320,641 -38.1% $24.9M 6.8% $48.0
Q4 2025 840,650 $32.5M 10.5% $38.6

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.

When did Davern Capital Partners, LP first disclose a RPRX position in 13F-HR filings?

Davern Capital Partners, LP first reported ROYALTY PHARMA PLC (RPRX) on its 13F-HR filing for the period ending 2025-12-31 (Q4 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.

What was Davern Capital Partners, LP's most recent quarter-over-quarter share-count change in RPRX?

Between Q1 2026 and Q2 2026, Davern Capital Partners, LP added 635,800 shares of RPRX (+122.3%), bringing the total reported position to 1,155,809 shares at a market value of $64.8M.

Does the implied price-per-share represent Davern Capital Partners, LP's cost basis in RPRX?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.